Skip to main content
SpringerLink
Log in

Current Surgical and Medical Oncological Treatment Approaches in Metastatic Gastric Cancer

  • Chapter
  • First Online:
Interdisciplinary Cancer Research

Part of the book series: Interdisciplinary Cancer Research

Abstract

The spread of tumor within the peritoneal cavity is termed peritoneal carcinomatosis (PC). The most common etiologies are gastric, colorectal, ovarian, and appendiceal cancers. Despite the development of medical oncologic treatments for this disease group, poor responses to systemic therapies are often observed. Among the reasons for these are challenges in peritoneal vascularization and the mesothelial-mesenchymal transition of peritoneal fibroblasts. Unfortunately, systemic treatments have not been successful in alleviating PC. Complications such as intra-abdominal acid, cachexia, sarcopenia, bowel, and ureteral obstructions make management more complex in these patients treated due to PC. In patients with PC, interdisciplinary approaches supported by combined medical oncology– and modern technology–based devices, such as concomitant cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) and pressurized intraperitoneal aerosol chemotherapy (PIPAC), offer hope to these patients. Successful outcomes have been achieved in colorectal, ovarian, and appendiceal cancer cases with concomitant systemic chemotherapy and CRS + HIPEC–supported surgeries. However, the main problem still lies in the treatment of metastatic gastric cancer. The aim of this chapter is to present innovative and modern medical oncologic and surgical approaches in this challenging and complex disease through an interdisciplinary approach.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Al-Batran SE, Hartmann JT, Probst S et al (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26:1435

    Google Scholar 

  • Alyami M, Gagniere J, Sgarbura O et al (2017) Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis. Euro J Surg Oncol 43:2178–2183

    Google Scholar 

  • Alyami M, Hübner M, Grass F et al (2019) Pressurized intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol 20:368–377

    Google Scholar 

  • Alyami M, Mercier F, Siebert M et al (2021) Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 47:128–133

    Google Scholar 

  • Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 376:687–697

    Google Scholar 

  • Bootsma S, Bijlsma MF, Vermeulen L (2023) The molecular biology of peritoneal metastatic disease. EMBO Mol Med 15:15914

    Google Scholar 

  • Di Giorgio A, Macrì A, Ferracci F et al (2023) 10 years of pressurized intraperitoneal aerosol chemotherapy (PIPAC): a systematic review and meta-analysis. Cancers 9:1125

    Google Scholar 

  • Fuchs CS, Tomasek J, Yong CJ et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomized, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31–39

    Google Scholar 

  • Giger-Pabst U, Tempfer CB (2018) How to perform safe and technically optimized pressurized intraperitoneal aerosol chemotherapy (PIPAC): experience after a consecutive series of 1200 procedures. J Gastrointest Surg 22:2187–2193

    Google Scholar 

  • Girshally R, Demtröder C, Albayrak N et al (2016) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 14:253

    Google Scholar 

  • Graversen M, Detlefsen S, Pfeiffer P et al (2018) Severe peritoneal sclerosis after repeated pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC OX): report of two cases and literature survey. Clin Exp Metastasis 35:103–108

    Google Scholar 

  • Grillo F, Fassan M, Sarocchi F et al (2016) HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice. World J Gastroenterol 14:5879–5887

    Google Scholar 

  • Harper MM, Kim J, Pandalai PK (2022) Current trends in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal disease from appendiceal and colorectal malignancies. J Clin Med 11:2840

    Google Scholar 

  • Hecht JR, Bang YJ, Qin SK et al (2016) Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC–a randomized phase III trial. J Clin Oncol 34:443–451

    Google Scholar 

  • Janjigian YY, Shitara K, Moehler M, Garrido et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomized, open-label, phase 3 trial. Lancet 398:27–40

    Google Scholar 

  • Kim G, Tan HL, Sundar R et al (2021) PIPAC-OX: a phase I study of oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy in patients with peritoneal metastases. Clin Cancer Res 27:1875–1881

    Google Scholar 

  • Li J, Guo T (2022) Role of peritoneal mesothelial cells in the progression of peritoneal metastases. Cancers 14:2856

    Google Scholar 

  • Marabelle A, Le DT, Ascierto PA et al (2020) Efficacy of Pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 1:1–10

    Google Scholar 

  • Montagnani F, Turrisi G, Marinozzi C et al (2011) Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. Gastric Cancer 14:50–55

    Google Scholar 

  • Reymond M, Demtroeder C, Solass W et al (2016) Electrostatic precipitation pressurized IntraPeritoneal aerosol chemotherapy (ePIPAC): first in-human application. Pleura Peritoneum 1:109–116

    Google Scholar 

  • Rha SY, Oh DY, Yañez P et al (2023) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomized, double-blind, phase 3 trial. Lancet Oncol 24:1181–1195

    Google Scholar 

  • Robella M, Hubner M, Sgarbura O et al (2022) Feasibility and safety of PIPAC combined with additional surgical procedures: PLUS study. Euro J Surg Oncol 48:2212–2217

    Google Scholar 

  • Sandoval P, Jiménez-Heffernan JA, Rynne-Vidal Á et al (2013) Carcinoma-associated fibroblasts derive from mesothelial cells via mesothelial-to-mesenchymal transition in peritoneal metastasis. J Pathol 231:517–531

    Google Scholar 

  • Sgarbura O, Eveno C, Alyami M et al (2022) Consensus statement for treatment protocols in pressurized intraperitoneal aerosol chemotherapy (PIPAC). Peritoneum 7:1–7

    Google Scholar 

  • Shitara K, Doi T, Dvorkin M et al (2018) Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 19:1437–1448

    Google Scholar 

  • Shitara K, Bang YJ, Iwasa S et al (2020a) Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med 382:2419–2430

    Google Scholar 

  • Shitara K, Van Cutsem E, Bang YJ et al (2020b) Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol 6:1571–1580

    Google Scholar 

  • Siegel RL, Miller KD, Fuchs HE et al (2021) Cancer statistics. CA Cancer J Clin 71:7–33

    Google Scholar 

  • Solass W, Sempoux C, Detlefsen S et al (2016) Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the peritoneal regression grading score (PRGS). Pleura Peritoneum 1:99–107

    Google Scholar 

  • Solass W, Sempoux C, Carr NJ et al (2019) Reproducibility of the peritoneal regression grading score for assessment of response to therapy in peritoneal metastasis. Histopathology 74:1014–1024

    Google Scholar 

  • Spratt JS, Adcock RA, Muskovin M et al (1980) Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 40:256–260

    Google Scholar 

  • Sugarbaker PH, Jablonski KA (1995) Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 221:124–132

    Google Scholar 

  • Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249

    Google Scholar 

  • Tabernero J, Hoff PM, Shen L et al (2018) Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomized, placebo-controlled phase 3 study. Lancet Oncol 19:1372–1384

    Google Scholar 

  • Thuss-Patience PC, Shah MA, Ohtsu A et al (2017) Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomized, open-label, adaptive, phase 2/3 study. Lancet Oncol 18:640–653

    Google Scholar 

  • Wagner AD, Syn NL, Moehler M et al (2017) Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 8:004064

    Google Scholar 

  • Wilke H, Muro K, Van Cutsem E et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomized phase 3 trial. Lancet Oncol 15:1224–1235

    Google Scholar 

Download references

Author Contributions

ÖD and MÖ designed the research study, wrote the manuscript. PÖ and TKG performed the research and analyzed the data. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript.

Ethics Approval and Consent to Participate

Since it was a book chapter, ethical approval was not needed.

Conflict of Interest

None of the authors has any conflict of interest to declare.

Declaration of Patient Consent

The authors certify that they have obtained all appropriate patient consent forms.

All authors read and approved the final version of the manuscript.

Funding

The authors received no financial support for the research, authorship, and/or publication of this chapter.

Author information

Authors and Affiliations

  1. Cerrahpaşa Faculty of Medicine, Department of General Surgery, İstanbul University, Istanbul, Turkey

    Pırıltı Özcan

  2. Department of Medical Oncology, University of Health Sciences, İstanbul Umraniye Training and Research Hospital, Istanbul, Turkey

    Tuğçe Kübra Güneş & Melike Özçelik

  3. Department of Surgical Oncology, University of Health Sciences, İstanbul Umraniye Training and Research Hospital, Istanbul, Turkey

    Ozgul Duzgun

Authors
  1. Pırıltı Özcan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tuğçe Kübra Güneş
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ozgul Duzgun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Melike Özçelik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ozgul Duzgun .

Rights and permissions

Reprints and permissions

Copyright information

© 2024 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Özcan, P., Güneş, T.K., Duzgun, O., Özçelik, M. (2024). Current Surgical and Medical Oncological Treatment Approaches in Metastatic Gastric Cancer. In: Interdisciplinary Cancer Research. Springer, Cham. https://doi.org/10.1007/16833_2024_220

Download citation

  • DOI: https://doi.org/10.1007/16833_2024_220

  • Published:

  • Publisher Name: Springer, Cham

Publish with us

Policies and ethics

Search

Navigation